|
James S. MacDonald, Ph.D., is executive vice president, preclinical development for Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation.
MacDonald is responsible for directing the activities surrounding the movement of new potential therapeutic entities from discovery research into and through the development process. His specific areas of involvement include those groups responsible for characterizing the potential adverse effects of new therapeutic entities and for characterizing the absorption, metabolism and distribution of such new entities in animals and humans. He also is involved with groups responsible for the synthesis of new drug substances, development of pharmaceutical formulations for these new drugs, and analysis of these drug substance and formulation entities.
MacDonald joined Schering-Plough in 1994 from Merck Research Laboratories, West Point, Pa., where he served as executive director of toxicology. During his 17-year employ at Merck, MacDonald held various positions of increasing responsibility in the department of safety assessment.
MacDonald earned a B.A. degree in chemistry and biology from DePauw University, Greencastle, Ind., and a Ph.D. degree in toxicology from the University of Cincinnati. He completed a post-doctoral research fellowship at Vanderbilt University and became a diplomate of the American Board of Toxicology in 1980.
MacDonald has been published extensively and has served on various scientific committees and boards. He has received a number of distinguished honors and academic awards, including the Robert A. Scala Award in Toxicology (2003); the DePauw University Distinguished Alumni Award (1994); and the Merck Board of Directors Scientific Award (1992).
MacDonald serves on the board of trustees of the International Life Science Institute/Health & Environmental Science Institute. He is a member of the Society of Toxicology, the International Society for Study of Xenobiotics and the PhRMA DruSafe Steering Committee.
| 